Mayo Clinic Laboratories > Genetics > Pharmacogenomics > Comprehensive panels

Comprehensive panels 

Optimize therapeutic outcomes

Research shows a significant percentage of patients possess genetic variants that impact therapeutic response, leading to a lack of treatment efficacy or treatment-related toxicity. Establishing a patient’s genetic profile through pharmacogenomic testing allows physicians to individualize treatment by selecting medications that optimize therapeutic efficacy while avoiding harmful drug reactions.

Our psychotropic and focused pharmacogenomic panels examine dozens of alleles on multiple genes to assess for known drug phenotype associations and identify variations associated with treatment response.

99%

99% of individuals carry clinically actionable variants affecting medication absorption, distribution, metabolism, and excretion1

Comprehensive panels Test menu

Comprehensive panels Comprehensive panels

Comprehensive panels

Key testing

  • PSYQP | Psychotropic Pharmacogenomics Gene Panel, Varies
    • Examines 23 genes (141 alleles) used to assess approximately 80 medications.
    • Identifies variation in genes known to be associated with response and/or risk of toxicity with psychotropic medications.
  • PGXQP | Focused Pharmacogenomics Panel, Varies
    • Examines 10 genes (82 alleles) used to assess more than 85 medications.
    • Delivers preemptive or reactive genotyping of patients for pharmacogenetic purposes.
    • Provides assessments for genes with strong drug phenotype associations and a high level of evidence for clinical use.

Highlights

Focused Pharmacogenomics Panel [Test in Focus]

Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.

Learn more
References
  1. Wang L, Scherer SE, Bielinski SJ, et al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022;24(5):1062-1072. doi:10.1016/j.gim.2022.01.022
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.